Search Result

Results for "

H2AX

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) AMPK (1) Amyloid-β (2) Apoptosis (30) Atg8/LC3 (1) ATM/ATR (6) Autophagy (2) Bcl-2 Family (4) Beclin1 (1) c-Myc (3) Casein Kinase (1) Caspase (5) CDK (3) Checkpoint Kinase (Chk) (6) DNA Alkylator/Crosslinker (1) DNA-PK (1) DNA/RNA Synthesis (7) EGFR (1) ERK (2) FABP (1) FAK (2) FLAP (1) Fluorescent Dye (1) GLUT (1) HDAC (2) Histone Methyltransferase (4) HSP (1) HSV (1) IAP (2) JAK (2) JNK (2) MDM-2/p53 (5) Mitochondrial Metabolism (1) Mitosis (1) Molecular Glues (1) mTOR (1) NF-κB (2) Notch (1) p62 (1) PAK (1) PARP (5) PERK (1) Phosphatase (2) PI3K (3) Polo-like Kinase (PLK) (2) RAD51 (1) Reactive Oxygen Species (ROS) (7) Reference Standards (3) Small Interfering RNA (siRNA) (3) SOD (1) Src (1) Telomerase (2) TOPK (1) Topoisomerase (4) TrxR (1) VEGFR (3) VRK (1)
By Research Areas:	Cancer (41) Infection (1) Neurological Disease (2)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-18174

Prexasertib Maximum Cited Publications 33 Publications Verification LY2606368	Checkpoint Kinase (Chk) Apoptosis	Cancer
Prexasertib (LY2606368) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a K_i of 0.9 nM and an IC₅₀ of <1 nM. Prexasertib inhibits CHK2 (IC₅₀=8 nM) and RSK1 (IC₅₀=9 nM). Prexasertib causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib shows potent anti-tumor activity ^[2].

HY-12037A

Rigosertib 5+ Cited Publications ON-01910	Polo-like Kinase (PLK) PI3K Apoptosis	Cancer
Rigosertib (ON-01910) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the PI3 kinase/Akt pathway, promots the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle ^[2]. Rigosertib is a selective and non-ATP-competitive inhibitor of PLK1 with an IC₅₀ of 9 nM .

HY-W1126504

ETN029 MC339	Notch	Cancer
ETN029 (MC339) is a selective DLL3 ligand. ETN029 labeled with ²²⁵Ac has dose-dependent cytotoxicity in SCLC, NEPC and metastatic melanoma cells and increases the phosphorylation of H2AX expression. ETN029 labeled with 177Lu shows rapid uptake persistent tumor retention and favorable tumor-to-kidney ratio. ETN029 can be used for cancers like SCLC and NEPC imaging and research ^[2].

HY-123834

FEN1-IN-1 5+ Cited Publications	FLAP ATM/ATR	Cancer
FEN1-IN-1 (compound 1) is a small molecule flap endonuclease 1 (FEN1) inhibitor with antitumor activity. FEN1-IN-1 binds to the active site of FEN1 and partly achieves inhibition by the co-ordination of Mg ²⁺ ions. FEN1-IN-1 initiaties a DNA damage response and activates the ATM checkpoint signalling pathway, the phosphorylation of histone H2AX and the ubiquitination of FANCD2 in mammalian cells. FEN1-IN-1 is promising for research of cancers .

HY-N0316

Mollugin 2 Publications Verification	JAK NF-κB Reactive Oxygen Species (ROS) Apoptosis VEGFR c-Myc	Cancer
Mollugin is an orally active and potent NF-κB inhibitor. Mollugin induces S-phase arrest of HepG2 cells, and increased intracellular reactive oxygen species (ROS) levels. Mollugin induces DNA damage in HepG2 cells, as well as an increase in the expression of p-H2AX. Mollugin shows anti-cancer effect by inhibiting TNF-α-induced NF-κB activation. Mollugin enhances the osteogenic action of BMP-2 (bone morphogenetic protein 2) via the p38-Smad signaling pathway ^[2] .

HY-18174A

Prexasertib dihydrochloride Maximum Cited Publications 33 Publications Verification LY2606368 dihydrochloride	Checkpoint Kinase (Chk) Apoptosis	Cancer
Prexasertib dihydrochloride (LY2606368 dihydrochloride) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a K_i of 0.9 nM and an IC₅₀ of <1 nM. Prexasertib dihydrochloride inhibits CHK2 (IC₅₀=8 nM) and RSK1 (IC₅₀=9 nM). Prexasertib dihydrochloride causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib dihydrochloride shows potent anti-tumor activity ^[2].

HY-101089

RHPS4 5 Publications Verification	Telomerase Apoptosis	Cancer
RHPS4 is a potent telomerase inhibitor (IC₅₀ = 0.33 μM). RHPS4 is a DNA damage inducer ^[2].

HY-122181

OTS186935 4 Publications Verification	Histone Methyltransferase	Cancer
OTS186935 is a potent protein methyltransferase *SUV39H2* inhibitor with an IC₅₀ of 6.49 nM. OTS186935 shows significant inhibition of tumor growth in mouse xenograft models without any detectable toxicity. OTS193320 regulates the production of γ-H2AX in cancer cells .

HY-12037

Rigosertib sodium 5+ Cited Publications ON-01910 sodium	Polo-like Kinase (PLK) PI3K Apoptosis	Cancer
Rigosertib sodium (ON-01910 sodium) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the PI3K/Akt pathway, promotes the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle ^[2]. Rigosertib sodium is a selective and non-ATP-competitive inhibitor of PLK1 with an IC₅₀ of 9 nM .

HY-117693

(E/Z)-Mirin 5+ Cited Publications	ATM/ATR	Cancer
(E/Z)-Mirin is a mixture of (E)-Mirin and Mirin ((Z)-Mirin) (HY-19959) configurations. Among them, Mirin is an inhibitor of MRN (Mre11-Rad50-Nbs1). Mirin prevents MRN-dependent ATM activation without affecting ATM protein kinase activity ^[2].

HY-163944

LL-K12-18	DNA/RNA Synthesis Molecular Glues CDK Apoptosis RAD51 ATM/ATR PARP	Cancer
LL-K12-18 is a CDK12 kinase inhibitor and a dual-site molecular glue. LL-K12-18 inhibits human CDK12 with an IC₅₀ value of 283.9 nM, and selectively degrades cyclin K via the ubiquitin-proteasome system by stabilizing the CDK12-DDB1 complex. LL-K12-18 downregulates DNA damage response genes, reduces the phosphorylation level of CTD Ser2 in RNA polymerase II, and modulates biomarkers such as ATM, RAD51, *γ-H2AX* and cleaved PARP, thereby effectively inducing apoptosis and inhibiting proliferation of breast cancer cells. LL-K12-18 exhibits high target selectivity and serves as a research tool for studies on triple-negative breast cancer ^[2].

HY-N2445

Flavokawain C 4 Publications Verification	Apoptosis Akt JNK PERK Caspase PARP MDM-2/p53 IAP Reactive Oxygen Species (ROS) SOD FABP Autophagy AMPK mTOR GLUT EGFR PI3K HSP VEGFR FAK	Cancer
Flavokawain C is an orally active natural chalcone. Flavokawain C inhibits the proliferation of various cancer cells. Flavokawain C upregulates GADD153 in cancer cells, inhibits the phosphorylation of Akt and JNK, suppresses early ERK phosphorylation, activates late ERK phosphorylation, activates caspase related subtypes, induces PARP-1 cleavage, causes upregulation of p21 and p27, downregulation of mutant p53 and anti-apoptotic IAP proteins, elevates intracellular ROS levels, reduces SOD activity, and induces apoptosis. Flavokawain C downregulates FABP4, induces autophagy in cancer cells, and activates the AMPK/mTOR pathway . Flavokawain C decreases the expression of glycolysis-related proteins GLUT1 and *HK2, and inhibits glycolysis in nasopharyngeal carcinoma cells. Flavokawain C inhibits the activation of the EGFR/PI3K/Akt/mTOR* signaling pathway and reduces the expression of HSP90B1. Flavokawain C inhibits angiogenesis by decreasing the expression of angiogenic proteins Ang-1 and VEGF in human umbilical vein endothelial cells. Flavokawain C increases *γ-H2AX* levels in cells, inhibits the phosphorylation of FAK, PI3K and AKT in cells, and induces DNA damage in cells. Flavokawain C exerts anti-tumor activity in multiple tumor xenograft mouse models. Flavokawain C is applicable to research related to colorectal cancer, colon adenocarcinoma, nephroblastoma, nasopharyngeal carcinoma and liver cancer ^[2] .

HY-122182

OTS193320	Histone Methyltransferase Apoptosis	Cancer
OTS193320, a imidazo[1,2-a]pyridine compound, is a SUV39H2 methyltransferase activity inhibitor. OTS193320 decreases global histone H3 lysine 9 tri-methylation levels in breast cancer cells and triggers apoptotic cell death. Combination of OTS193320 with Doxorubicin (HY-15142A) results in reduction of γ-H2AX levels as well as cancer cell viability compared to a single agent OTS193320 or DOX .

HY-103241

Ro 90-7501 3 Publications Verification	Amyloid-β ATM/ATR Phosphatase Apoptosis	Neurological Disease Cancer
Ro 90-7501 is an amyloid β₄₂ (Aβ₄₂) fibril assembly inhibitor that reduces Aβ₄₂-induced cytotoxicity (EC₅₀ of 2 μM). Ro 90-7501 inhibits ATM phosphorylation and DNA repair. RO 90-7501 selectively enhances toll-like receptor 3 (TLR3) and RIG-I-like receptor (RLR) ligand-induced IFN-β gene expression and antiviral response ^[2]. Ro 90-7501 also inhibits protein phosphatase 5 (PP5) in a TPR-dependent manner . Ro 90-7501 has significant radiosensitizing effects on cervical cancer cells .

HY-18174E

Prexasertib dimesylate Maximum Cited Publications 33 Publications Verification LY2606368 dimesylate	Checkpoint Kinase (Chk) Apoptosis	Cancer
Prexasertib dimesylate (LY2606368 dimesylate) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a K_i of 0.9 nM and an IC₅₀ of <1 nM. Prexasertib dimesylate inhibits CHK2 (IC₅₀=8 nM) and RSK1 (IC₅₀=9 nM). Prexasertib dimesylate causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib dimesylate shows potent anti-tumor activity ^[2].

HY-122181B

OTS186935 hydrochloride 4 Publications Verification	Histone Methyltransferase	Cancer
OTS186935 hydrochloride is a potent protein methyltransferase *SUV39H2* inhibitor with an IC₅₀ of 6.49 nM. OTS186935 hydrochloride shows significant inhibition of tumor growth in mouse xenograft models without any detectable toxicity. OTS193320 hydrochloride regulates the production of γ-H2AX in cancer cells .

HY-158975

VRK1/CK1-IN-1	Casein Kinase VRK	Cancer
VRK1/CK1-IN-1 (compound 36) is a dual VRK1 and CK1 family inhibitor, with a K_i of 37.9 nM against human VRK1, 8.3 nM against human CK1δ, and 7.8 nM against human CK1ε. VRK1/CK1-IN-1 exhibits extremely low activity against *VRK2*. VRK1/CK1-IN-1 can be used in studies related to p53-deficient tumors .

HY-113041

Prostaglandin A2 PGA2; Medullin	Apoptosis Caspase PARP ERK MDM-2/p53 JNK HSV	Infection Cancer
Prostaglandin A2 (PGA2) is a Cyclopentenone prostaglandin. Prostaglandin A2 induces Caspase-dependent Apoptosis, activates p53. Prostaglandin A2 activates *ERK2* and JNK1/SAPK. Prostaglandin A2 shows antiviral activity against HSV-1. Prostaglandin A2 has anti-tumor effects. Prostaglandin A2 can be used for the research of colorectal cancer, colorectal carcinoma, breast carcinoma, and herpetic keratitis ^[2] .

HY-RS05957

H2AX Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
H2AX Human Pre-designed siRNA Set A contains three designed siRNAs for H2AX gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

H2AX Human Pre-designed siRNA Set A H2AX Human Pre-designed siRNA Set A

HY-132972

TrxR-IN-2	TrxR Reactive Oxygen Species (ROS) Autophagy Atg8/LC3 Beclin1 p62	Cancer
TrxR-IN-2 is a thioredoxin reductase (TrxR) inhibitor. TrxR-IN-2 increases reactive oxidative species (ROS) levels and decreases mitochondrial transmembrane potential levels. TrxR-IN-2 triggers DNA damage via *H2AX* regulation, and induces autophagy via LC3, beclin-1, and p62 regulation. TrxR-IN-2 can be used for the research of drug-resistant hepatocellular carcinoma^[1].

HY-RS16644

H2ax Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
H2ax Mouse Pre-designed siRNA Set A contains three designed siRNAs for H2ax gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

H2ax Mouse Pre-designed siRNA Set A H2ax Mouse Pre-designed siRNA Set A

HY-122860

SKLB-C05	TOPK Apoptosis c-Myc MDM-2/p53 FAK Src Mitosis	Cancer
SKLB-C05 is a novel selective, orally active TOPK inhibitor, with an IC₅₀ of 0.5 nM. SKLB-C05 selectively inhibit TOPK kinase. SKLB-C05 induces Apoptosis, downregulates c-Myc, *γ-H2AX, activates p53, blocks FAK/Src* medicated migration-related signaling. SKLB-C05 disturbs cell mitosis. SKLB-C05 shows anticancer activity only against TOPK-positive colorectal cancer .

HY-RS23078

H2ax Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
H2ax Rat Pre-designed siRNA Set A contains three designed siRNAs for H2ax gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

H2ax Rat Pre-designed siRNA Set A H2ax Rat Pre-designed siRNA Set A

HY-175700

YCJ-02	Topoisomerase Apoptosis	Cancer
YCJ-02 is a selective Topoisomerase I (Top I) inhibitor. YCJ-02 can inhibit cell proliferation and induce apoptosis and G2/M phase arrest. YCJ-02 can induce DNA damage and increaseγ-H2AX levels. YCJ-02 can promote Top I deqradation via a ubiquitin/26S proteasome pathway. YCJ-02 increases the expressions of pro-apoptotic proteins Bad, Bax, and cleaved caspase-3. YCJ-02 shows broad-spectrum antitumor activity. YCJ-02 can be used for the research of cancer, such as intrahepatic cholangiocarcinoma (ICC) .

HY-W414334

ICR-191 dihydrochloride	DNA/RNA Synthesis Fluorescent Dye	Cancer
ICR-191 dihydrochloride enhances Cisplatin (HY-17394)- DNA binding and sensitizes cells to cisplatin. ICR-191 dihydrochloride induces a significant increase in the expression of phosphorylated H2AX (γH2AX), particularly in DNA-replicating cells. ICR-191 dihydrochloride can be used for the study of leukemia ^[2].

HY-121777

SFOM-0046	DNA/RNA Synthesis	Cancer
SFOM-0046 arrests cell cycle in S-phase and causes DNA replication stress leading to the phosphorylation of H2AX into γ-H2AX. SFOM-0046 induces DNA damages. SFOM-0046 is a potent anticancer agent .

HY-174989

ATM-IN-2	ATM/ATR Apoptosis	Cancer
ATM-IN-2 is a selective and orally active ATM inhibitor with an IC₅₀ of 4 nM. ATM-IN-2 exhibits excellent kinase selectivity (>700-fold over PIKK family members). ATM-IN-2 exerts its anti-tumor effect by inhibiting ATM phosphorylation and the downstream signaling pathways (p53, H2AX), and promotes cell apoptosis. ATM-IN-2 can be used for the study of chemosensitizer candidate such as colon cancer .

HY-N0316R

Mollugin (Standard)	JAK Reference Standards NF-κB Reactive Oxygen Species (ROS) Apoptosis VEGFR c-Myc	Cancer
Mollugin (Standard) is the analytical standard of Mollugin. This product is intended for research and analytical applications. Mollugin is an orally active and potent NF-κB inhibitor. Mollugin induces S-phase arrest of HepG2 cells, and increased intracellular reactive oxygen species (ROS) levels. Mollugin induces DNA damage in HepG2 cells, as well as an increase in the expression of p-H2AX. Mollugin shows anti-cancer effect by inhibiting TNF-α-induced NF-κB activation. Mollugin enhances the osteogenic action of BMP-2 (bone morphogenetic protein 2) via the p38-Smad signaling pathway ^[2] .

HY-18174H

Prexasertib lactate LY2606368 lactate	Checkpoint Kinase (Chk) Apoptosis DNA/RNA Synthesis	Cancer
Prexasertib lactate (LY2606368 lactate) is the lactate form of Prexasertib (HY-18174). Prexasertib lactate is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a K_i of 0.9 nM and an IC₅₀ of <1 nM. Prexasertib lactate inhibits *CHK2* (IC₅₀=8 nM) and RSK1 (IC₅₀=9 nM). Prexasertib lactate causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib lactate shows potent anti-tumor activity ^[2].

HY-122181A

OTS186935 trihydrochloride	Histone Methyltransferase	Cancer
OTS186935 trihydrochloride is a protein methyltransferase *SUV39H2* inhibitor with an IC₅₀ of 6.49 nM. OTS186935 trihydrochloride shows significant inhibition of tumor growth in mouse xenograft models without any detectable toxicity. OTS186935 trihydrochloride regulates the production of γ-H2AX in cancer cells .

HY-162985

JHD205	CDK	Cancer
JHD205 is a CDK4/6 inhibitor that induces apoptosis and DNA damage. JHD205 inhibits DNA repair by upregulating Caspase3 and p-H2AX. JHD205 has superior potency to Abemaciclib (HY-16297A) in a xenograft chick embryo breast cancer model. .

HY-168877

FMP	MDM-2/p53 Reactive Oxygen Species (ROS) Apoptosis Caspase PARP Bcl-2 Family	Cancer
FMP is a Platinum(IV) complexe. FMP significantly upregulates the expression of *γ-H2AX* and p53. FMP increases the production of ROS. FMP markedly upregulates the expressions of Apoptosis-related proteins (DR5, Fas, caspase-8, Cyt-c, caspase-3, cleaved-PARP1, Bax). FMP shows antiproliferative activity against breast cancer .

HY-117688

WJ35435	HDAC Topoisomerase Apoptosis	Cancer
WJ35435 is a dual-targeted anticancer hybrid that induces anti-HDAC (in particular HDAC1 and HDAC6) and anti-topoisomerase I activities that causes DNA damage associated with a low DNA repair capability and induces cell cycle arrest at G1- and G2-phase to apoptosis. WJ35435 induces histone H3 acetylation and phosphorylation, α-tubulin acetylation and γ-H2AX formation to achieve anti-HDAC effect. WJ35435 is promising for research of cancer .

HY-145289

Antitumor agent-37	Apoptosis	Cancer
Antitumor agent-37 possesses potent anti-proliferative and anti-metastasis activities. Antitumor agent-37 induces serious DNA damage and further leads to high expression of γ-H2AX and p53. Antitumor agent-37 promotes apoptosis of tumor cells through mitochondrial apoptotic pathway Bcl-2/Bax/caspase3. Antitumor agent-37 significantly improves immune response through restraining the expression of PD-L1 to increase CD3+ and CD8+ T infiltrating cells in tumor tissues .

HY-145288

Antitumor agent-36	Apoptosis	Cancer
Antitumor agent-36 possesses potent anti-proliferative and anti-metastasis activities. Antitumor agent-36 induces serious DNA damage and further leads to high expression of γ-H2AX and p53. Antitumor agent-36 promotes apoptosis of tumor cells through mitochondrial apoptotic pathway Bcl-2/Bax/caspase3. Antitumor agent-36 significantly improves immune response through restraining the expression of PD-L1 to increase CD3+ and CD8+ T infiltrating cells in tumor tissues .

HY-18174B

Prexasertib Mesylate Hydrate LY2606368 Mesylate Hydrate; LY2940930	Checkpoint Kinase (Chk) Apoptosis	Cancer
Prexasertib Mesylate Hydrate (LY2606368 Mesylate Hydrate) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a K_i of 0.9 nM and an IC₅₀ of <1 nM. Prexasertib Mesylate Hydrate inhibits CHK2 (IC₅₀=8 nM) and RSK1 (IC₅₀=9 nM). Prexasertib Mesylate Hydrate causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib Mesylate Hydrate shows potent anti-tumor activity ^[2].

HY-18174C

Prexasertib mesylate LY2606368 mesylate	Checkpoint Kinase (Chk) DNA/RNA Synthesis Apoptosis	Cancer
Prexasertib mesylate (LY2606368 mesylate) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a K_i of 0.9 nM and an IC₅₀ of <1 nM. Prexasertib mesylate inhibits CHK2 (IC₅₀=8 nM) and RSK1 (IC₅₀=9 nM). Prexasertib mesylate causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib mesylate shows potent anti-tumor activity ^[2].

HY-181557

SY-589	DNA Alkylator/Crosslinker DNA/RNA Synthesis Apoptosis	Cancer
SY-589 is an orally active DNA polymerase Polθ helicase domain inhibitor (IC₅₀=2.29 nM) and DNA damage inducer. SY-589 inhibits the ATPase activity of the Polθ helicase domain and blocks the Polθ-mediated microhomology-mediated end joining (MMEJ) DNA repair pathway (IC₅₀=0.85 nM). SY-589 also induces the accumulation of DNA double-strand breaks by increasing *γ-H2AX* levels. SY-589 exerts antiproliferative effects on BRCA2-deficient cells and is used in the research of HR-deficient tumors .

HY-181018

Topo I/DDX5-IN-1	Topoisomerase PAK Bcl-2 Family IAP Reactive Oxygen Species (ROS) Apoptosis	Cancer
Topo I/DDX5-IN-1 (Compound A10) is a Topo I and DDX5 inhibitor. Topo I/DDX5-IN-1 inhibits Topo I activity, binds to DDX5, and suppresses DDX5 function. Topo I/DDX5-IN-1 increases expression of *γ-H2AX* and p21, suppresses the expression of antiapoptotic proteins (Bcl-2 and XIAP), stimulates ROS generation, and triggers Apoptosis. Topo I/DDX5-IN-1 exhibits anticancer activity against pancreatic cancer, non-small cell lung cancer, skin cancer, and colorectal cancer .

HY-183330

Topo I/II-IN-3	Topoisomerase Reactive Oxygen Species (ROS) Apoptosis MDM-2/p53 Caspase Bcl-2 Family	Cancer
Topo I/II-IN-3 is a dual inhibitor of topoisomerase I/II (topoisomerase I/II), with an IC₅₀ of 8.99 μM against Topo I and an IC₅₀ of 26.92 μM against Topo II. Topo I/II-IN-3 induces DNA damage, elevates intracellular ROS levels, activates the mitochondrial apoptosis pathway, and exerts cytotoxicity against cancer cells. Topo I/II-IN-3 upregulates the expression of *γ-H2AX, p53, activated caspase-9, Bax* and activated caspase-3, while downregulating the expression of *Bcl-2*. Topo I/II-IN-3 can be used in research related to breast cancer, liver cancer and gastric cancer .

HY-181678

DNA-PK/HDAC6-IN-1	DNA-PK HDAC Apoptosis Mitochondrial Metabolism DNA/RNA Synthesis	Cancer
DNA-PK/HDAC6-IN-1 is a selcetive and orally active dual DNA-PK and HDAC6 inhibitor with IC₅₀ values of 84.2 and 64.8 nM. DNA-PK/HDAC6-IN-1 suppresses cancer cells proliferation, induces cancer cell cycle G2/M arrest, apoptosis, and decreases the mitochondrial membrane potential. DNA-PK/HDAC6-IN-1 induces DNA damage and elevates γ-H2AX levels. DNA-PK/HDAC6-IN-1 exhibits antitumor efficacy in AML animal mouse model. DNA-PK/HDAC6-IN-1 can be used for the research of acute myeloid leukemia .

HY-101089R

RHPS4 (Standard)	Telomerase Reference Standards Apoptosis	Cancer
RHPS4 (Standard) is the analytical standard of RHPS4 (HY-101089). This product is intended for research and analytical applications. RHPS4 is a potent telomerase inhibitor (IC50 = 0.33 μM). RHPS4 is a DNA damage inducer ^[2].

HY-103241R

Ro 90-7501 (Standard)	Reference Standards Amyloid-β ATM/ATR Phosphatase Apoptosis	Neurological Disease Cancer
Ro 90-7501 (Standard) is the analytical standard of Ro 90-7501 (HY-103241). This product is intended for research and analytical applications. Ro 90-7501 is an amyloid β42 (Aβ42) fibril assembly inhibitor that reduces Aβ42-induced cytotoxicity (EC₅₀ of 2 μM). Ro 90-7501 inhibits ATM phosphorylation and DNA repair. RO 90-7501 selectively enhances toll-like receptor 3 (TLR3) and RIG-I-like receptor (RLR) ligand-induced IFN-β gene expression and antiviral response ^[2]. Ro 90-7501 also inhibits protein phosphatase 5 (PP5) in a TPR-dependent manner . Ro 90-7501 has significant radiosensitizing effects on cervical cancer cells .

HY-167237

Calactin	Apoptosis Caspase CDK PARP Bcl-2 Family ERK	Cancer
Calactin is a glycoside that can be isolated from Asclepias curassavica L.. Calactin activates caspase-3, caspase-8, caspase-9, and phosphorylates ERK. Calactin induces DNA damage, apoptosis, PARP cleavage, G2/M phase cell cycle arrest, shifts *Bax/Bcl-2* expression, and shows anti-proliferation effects in leukemia cells. Calactin can be used for the research of leukemia .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0316

Mollugin 2 Publications Verification	Monophenols Classification of Application Fields Terpenoids Sesquiterpenes Rubiaceae Phenols Plants Disease Research Fields Rubia cordifolia L. Source Classification Cancer	JAK NF-κB Reactive Oxygen Species (ROS) Apoptosis VEGFR c-Myc
Mollugin is an orally active and potent NF-κB inhibitor. Mollugin induces S-phase arrest of HepG2 cells, and increased intracellular reactive oxygen species (ROS) levels. Mollugin induces DNA damage in HepG2 cells, as well as an increase in the expression of p-H2AX. Mollugin shows anti-cancer effect by inhibiting TNF-α-induced NF-κB activation. Mollugin enhances the osteogenic action of BMP-2 (bone morphogenetic protein 2) via the p38-Smad signaling pathway ^[2] .

HY-N2445

Flavokawain C 4 Publications Verification	Structural Classification Classification of Application Fields Piperaceae Plants Chalcones Flavonoids other families Phenols Polyphenols Piper methysticum G.Forst. Disease Research Fields Source Classification Cancer	Apoptosis Akt JNK PERK Caspase PARP MDM-2/p53 IAP Reactive Oxygen Species (ROS) SOD FABP Autophagy AMPK mTOR GLUT EGFR PI3K HSP VEGFR FAK
Flavokawain C is an orally active natural chalcone. Flavokawain C inhibits the proliferation of various cancer cells. Flavokawain C upregulates GADD153 in cancer cells, inhibits the phosphorylation of Akt and JNK, suppresses early ERK phosphorylation, activates late ERK phosphorylation, activates caspase related subtypes, induces PARP-1 cleavage, causes upregulation of p21 and p27, downregulation of mutant p53 and anti-apoptotic IAP proteins, elevates intracellular ROS levels, reduces SOD activity, and induces apoptosis. Flavokawain C downregulates FABP4, induces autophagy in cancer cells, and activates the AMPK/mTOR pathway . Flavokawain C decreases the expression of glycolysis-related proteins GLUT1 and *HK2, and inhibits glycolysis in nasopharyngeal carcinoma cells. Flavokawain C inhibits the activation of the EGFR/PI3K/Akt/mTOR* signaling pathway and reduces the expression of HSP90B1. Flavokawain C inhibits angiogenesis by decreasing the expression of angiogenic proteins Ang-1 and VEGF in human umbilical vein endothelial cells. Flavokawain C increases *γ-H2AX* levels in cells, inhibits the phosphorylation of FAK, PI3K and AKT in cells, and induces DNA damage in cells. Flavokawain C exerts anti-tumor activity in multiple tumor xenograft mouse models. Flavokawain C is applicable to research related to colorectal cancer, colon adenocarcinoma, nephroblastoma, nasopharyngeal carcinoma and liver cancer ^[2] .

HY-N0316R

Mollugin (Standard)	Structural Classification Monophenols Terpenoids Sesquiterpenes Rubiaceae Phenols Plants Rubia cordifolia L. Source Classification	JAK Reference Standards NF-κB Reactive Oxygen Species (ROS) Apoptosis VEGFR c-Myc
Mollugin (Standard) is the analytical standard of Mollugin. This product is intended for research and analytical applications. Mollugin is an orally active and potent NF-κB inhibitor. Mollugin induces S-phase arrest of HepG2 cells, and increased intracellular reactive oxygen species (ROS) levels. Mollugin induces DNA damage in HepG2 cells, as well as an increase in the expression of p-H2AX. Mollugin shows anti-cancer effect by inhibiting TNF-α-induced NF-κB activation. Mollugin enhances the osteogenic action of BMP-2 (bone morphogenetic protein 2) via the p38-Smad signaling pathway ^[2] .

HY-167237

Calactin	Apocynaceae Asclepias curassavica L. Triterpenes Structural Classification Terpenoids Plants Source Classification	Apoptosis Caspase CDK PARP Bcl-2 Family ERK
Calactin is a glycoside that can be isolated from Asclepias curassavica L.. Calactin activates caspase-3, caspase-8, caspase-9, and phosphorylates ERK. Calactin induces DNA damage, apoptosis, PARP cleavage, G2/M phase cell cycle arrest, shifts *Bax/Bcl-2* expression, and shows anti-proliferation effects in leukemia cells. Calactin can be used for the research of leukemia .

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P705951

	H2AX Protein, Human (GST) H2A histone family member X ; H2A histone family member X; H2A.FX; H2A.X; H2a/x; H2AFX; H2AX; H2AX_HUMAN; Histone H2A.X	Human	E. coli

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (4) Rabbit (6)
Reactivity:	Xenopus (1) Human (9) C. elegans (1) Rat (5) Mouse (7) broad mammalian (1) Drosophila (1) Monkey (1) Zebrafish (1)
Application:	IHC-P (5) ICC/IF (8) IF-Tissue (2) IP (6) WB (10) FC (2) ELISA (1)
Isotype:	IgG (6) IgG1 (4)
Conjugation:	Non-conjugated (10)
Clonality:	Monoclonal (5) Monoclonal Antibody (1) Recombinant (3)
Modification:	Phosphorylated (4) Unmodified (2)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P84123

	H2AFX Antibody (YA3820) H2AX; H2A.X; H2A/X	WB, IHC-P, ICC/IF, FC	Human
	H2AFX Antibody (YA3820) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to H2AFX.

HY-P84123A

	H2AFX Antibody (YA3820)(PBS only) H2AX; H2A.X; H2A/X	WB, IHC-P, ICC/IF, FC	Human
	H2AFX Antibody (YA3820) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to H2AFX.

HY-P86516

	Phospho-Histone H2A.X(Ser139) Antibody (YA6208) H2AFX; H2AX; Histone H2A.x; H2a/x	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Phospho-Histone H2A.X(Ser139) Antibody (YA6208) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Histone H2A.X(Ser139).

HY-P80941

	*Phospho-Histone H2A.X* (Ser139) Antibody (YA844)** 1 Publications Verification H2A.X; H2AFX; H2a/x; HIST5-2AX; Histone H2A.X; gamma H2A.X	WB, ICC/IF	Human, Mouse
	Phospho-Histone H2A.X (Ser139) Antibody (YA844) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Phospho-Histone H2A.X (Ser139).

HY-P80941A

	*Phospho-Histone H2A.X* (Ser139) Antibody (YA844)(PBS only)** H2A.X; H2AFX; H2a/x; HIST5-2AX; Histone H2A.X; gamma H2A.X	WB, ICC/IF	Human, Mouse
	Phospho-Histone H2A.X (Ser139) Antibody (YA844) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Phospho-Histone H2A.X (Ser139).

HY-P80161

	*Histone H2A.X* Antibody (YA380)** 2 Publications Verification	WB, ICC/IF, IHC-P, IP	Human, Mouse, Rat
	Histone H2A.X Antibody (YA380) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Histone H2A.X.

HY-P810603

	Histone H2A Acetyl Antibody H2A histone family member X; H2A histone family member X; H2A.FX; H2A.X; H2a/x; H2AFX; H2AX; H2AX_HUMAN; Histone H2A.X	WB, IP, IF-Tissue, ICC/IF, IP	broad mammalian, Zebrafish, Drosophila, Xenopus, C. elegans
	Histone H2A Acetyl Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to Histone H2A Acetyl.

HY-P80463

	*Phospho-Histone H2A.X* (Ser139) Antibody (YA190)**	WB, IHC-P, ICC/IF, IF-Tissue	Human, Mouse, Rat, Monkey
	Phospho-Histone H2A.X (Ser139) Antibody (YA190) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Histone H2A.X (Ser139).

HY-P80821

	*Phospho-Histone H2A.X* (Ser139) Antibody (YA191)** 2 Publications Verification H2A.X; H2AFX; H2a/x; HIST5-2AX; Histone H2A.X; gamma H2A.X	WB, IP	Human, Mouse, Rat
	Phospho-Histone H2A.X (Ser139) Antibody (YA191) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Histone H2A.X (Ser139).

HY-P80821A

	*Phospho-Histone H2A.X* (Ser139) Antibody (YA191)(PBS only)** H2A.X; H2AFX; H2a/x; HIST5-2AX; Histone H2A.X; gamma H2A.X	WB, IP	Human, Mouse, Rat
	Phospho-Histone H2A.X (Ser139) Antibody (YA191) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Histone H2A.X (Ser139).

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks